Prosight Management, LP Cytom X Therapeutics, Inc. Transaction History
Prosight Management, LP
- $369 Million
- Q2 2025
A detailed history of Prosight Management, LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 3,517,113 shares of CTMX stock, worth $6.54 Million. This represents 2.16% of its overall portfolio holdings.
Number of Shares
3,517,113
Previous 3,930,008
10.51%
Holding current value
$6.54 Million
Previous $2.52 Million
217.42%
% of portfolio
2.16%
Previous 0.9%
Shares
4 transactions
Others Institutions Holding CTMX
# of Institutions
88Shares Held
123MCall Options Held
305KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$26 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$20.6 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$17.4 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$15.7 Million0.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.08MShares$15 Million0.04% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $123M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...